Not yet recruiting
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
NCT07053020· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Gautam Borthakur, MBBS
Not yet recruiting
iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer
NCT07105020· M.D. Anderson Cancer Center· Source
Contact: Lorna McNeill, MPH,PHD
Not yet recruiting
Food is Medicine in Survivorship: Examining the Feasibility and Impact of a Scalable Food Delivery and Culinary Medicine Program (FoodiiS) Among Pediatric Cancer Survivors and Their Families
NCT07218328· M.D. Anderson Cancer Center· Source
Contact: Margaret Raber, DRPH
Not yet recruiting
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
NCT07164469· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Yago Nieto, MD,PHD
Recruiting
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
NCT07444606· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Christopher Alvarez-Breckenridge, MD, PHD
Not yet recruiting
Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
NCT07414979· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Isabella Glitza, MD, PHD
Recruiting
Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
NCT07179809· M.D. Anderson Cancer Center· Source
Contact: Meroe Morse, MD
Recruiting
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT07269470· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Fadi Haddad, MD
Recruiting
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
NCT07444619· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Brandon D Brown, MD
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820· Phase 2· Elevar Therapeutics· Source
Contact: Jordi Rodon Ahnert, MD, PhD (principal investigator)
Active, not recruiting
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
NCT07411586· Phase 1· M.D. Anderson Cancer Center· Source
Recruiting
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
NCT07444632· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Yago Nieto, MD, PHD
Recruiting
Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital
NCT07591701· M.D. Anderson Cancer Center· Source
Contact: Debanjan Pain, MD
Recruiting
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
NCT07382726· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Marcelo V Negrao, MD
Recruiting
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
NCT07415005· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Yasir Y Elamin, MD
Recruiting
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
NCT07076498· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Gregory Friedman, MD
Recruiting
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
NCT07298083· M.D. Anderson Cancer Center· Source
Contact: Keila Torres, MD,PHD
Recruiting
Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity
NCT06909201· M.D. Anderson Cancer Center· Source
Contact: Joshua Niedzielski, PHD
Recruiting
NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer
NCT07224152· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Aileen Chen, MD
Recruiting
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
NCT07187869· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Matthew Campbell
Recruiting
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
NCT07218315· M.D. Anderson Cancer Center· Source
Contact: Victoria E Banuchi, MPH
Recruiting
Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
NCT07127926· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Amin Alousi, MD
Active, not recruiting
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
NCT07153796· Phase 1/2· M.D. Anderson Cancer Center· Source
Recruiting
A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)
NCT07298096· M.D. Anderson Cancer Center· Source
Contact: Varshana Gurusamy, MD
Recruiting
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
NCT07128381· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Naveen Pemmaraju, MD
Recruiting
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
NCT07053033· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Subha Perni, MD
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805· Phase 1· Pfizer· Source
Recruiting
Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)
NCT07101432· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Gohar Manzar, MD
Recruiting
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
NCT07187778· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Eric Jonasch, MD
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559· Phase 2· ALX Oncology Inc.· Source
Contact: Cheng Quah, MD
Recruiting
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
NCT07193550· Phase 2· M.D. Anderson Cancer Center· Source
Contact: John Livingston, MD
Recruiting
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
NCT07116486· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Simone Krebs, MD
Recruiting
Self-sampling to Optimize Anal Lesion Outcomes
NCT07192055· Medical College of Wisconsin· Source
Contact: Craig Messick, MD
Recruiting
Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes
NCT07220096· M.D. Anderson Cancer Center· Source
Contact: Eric Singhi, MD
Recruiting
Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care
NCT06850402· M.D. Anderson Cancer Center· Source
Contact: Kathleen M Schmeler, MD
Recruiting
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
NCT07011654· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Clinton Yam, MD
Recruiting
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
NCT07049848· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Ahsan S Farooqi, MD, PHD
Recruiting
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
NCT07053059· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Elias Jabbour, MD
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source
Contact: Relay Therapeutics, Inc
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
NCT06959550· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Saurav Haldar, MD
Recruiting
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
NCT06769490· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Ghayas Issa, MD
Recruiting
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
NCT06826768· Phase 1· M.D. Anderson Cancer Center· Source
Contact: Bilal Siddiqui, MD
Recruiting
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
NCT06759701· Early phase 1· M.D. Anderson Cancer Center· Source
Contact: Justin Gregg, MD
Recruiting
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT06858735· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Eugene Koay, MD,PHD
Recruiting
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
NCT06919874· M.D. Anderson Cancer Center· Source
Contact: Kathrin Milbury, MA,PHD
Recruiting
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
NCT06811233· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Maro Ohanian, DO
Active, not recruiting
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT06708949· Phase 2· M.D. Anderson Cancer Center· Source
Recruiting
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
NCT06807606· Phase 2· M.D. Anderson Cancer Center· Source
Contact: Warren Fingrut, MD
Recruiting
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
NCT06672575· Phase 1/2· M.D. Anderson Cancer Center· Source
Contact: Evguenia Gachimova
Showing 50 of 71.